THG provides global payer research, strategic planning and global value dossiers for biopharmaceutical products.
THG, together with UBC’s existing value strategy and research services, will be led by THG’s Robert Hollamby, who has been appointed senior vice president at UBC.
UBC president Mark Clein said the addition of THG expands their capabilities and geographic reach and allows them to launch a comprehensive practice.
Hollamby said by combining THG’s global payer expertise and research with UBC’s scale and its portfolio of scientific and late stage research capabilities, they have strengthened their ability to deliver significant value and provide exciting new opportunities for clients throughout the industry.